Uncategorized

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, announced the presentation of compelling preclinical data at the Cellicon Valley 2023 Meeting in Philadelphia, PA.

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic Read More »

CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels

CymaBay Therapeutics, Inc. announced new findings from a post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis demonstrating baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31.

CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels Read More »

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa

UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study with oral orismilast in adult patients with HS.

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa Read More »

BioInvent Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces strong interim safety data from its Phase 1/2a trial of its first-in-class anti-TNFR2 antibody BI-1808 in advanced malignancies.

BioInvent Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with anti-TNFR2 Antibody BI-1808 in Advanced Malignancies Read More »

Scroll to Top